Medexus Pharmaceuticals Inc. (MEDXF)
| Previous Close | 2.4400 |
| Open | 2.4600 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 2.3700 - 2.4600 |
| 52 Week Range | 1.2500 - 3.5000 |
| Volume | |
| Avg. Volume | 7,795 |
| Market Cap | 46.826M |
| Beta (5Y Monthly) | 1.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1230 |
| Earnings Date | Feb 28, 2022 - Mar 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.00 |
- GlobeNewswire
Medexus Announces Record Fiscal Q1 2023 Revenue of US$23.0 Million, a 33% Increase versus Fiscal Q1 2022
Results include first U.S. revenue from Gleolan, full commercial launch expected in fiscal Q2 Treosulfan NDA resubmitted to the FDA, regulatory milestone payments deferred to October 2023 Management to host conference call at 8:00 AM Eastern Time on Tuesday, August 9, 2022 TORONTO and CHICAGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company’s first fisc
- GlobeNewswire
Medexus Schedules First Quarter 2023 Conference Call
TORONTO and CHICAGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Tuesday, August 9, 2022 to discuss Medexus’s results for its first quarter ended June 30, 2022. Medexus expects to file its financial statements and MD&A after markets close on August 8, 2022. To participate in the call, please dial the following numbers: 888-506-0062 (toll-free) for Canadian and U.S. callers+1 973-528-0011
- GlobeNewswire
Treosulfan NDA Resubmitted to FDA
FDA decision expected within six months of acceptancePivotal phase 3 clinical trial of treosulfan met primary endpoint and key secondary endpoints TORONTO and CHICAGO, July 25, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) and medac, a strategic partner of Medexus, are pleased to announce that medac has resubmitted its New Drug Application for treosulfan (NDA) with the U.S. Food and Drug Administration (FDA). The current submission was a response to the FDA
